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Products Liability-Drugs and Cosmetics
Page Keeton*
I. INTRODUCTION
Much has been written by judges and scholars about abrogation of
both the requirement of privity for recovery on warranty theories and
the prerequisite of a finding of negligence for recovery on a tort theory
against manufacturers and other sellers of all kinds of products.' As a
consequence of this abrogation, the courts in some states have completed
the change-over from a fault to a strict liability theory of recovery for
harm resulting from unintended and latent dangerous conditions of
products.2 Moreover, removal of initial restrictions limiting strict liabil-
ity to users and consumers is proceeding apace, and the logical extension
of strict liability to bystanders has already been accomplished in several
jurisdictions. 3 Confusion and uncertainty remain, however, as to what
actual impact these assaults on fault have had with reference to the legal
remedies for physical harm caused by inherent risks attendant upon the
use of products, such as drugs and cosmetics, that are constructed as
they were intended to be.
To date, it has been erroneously assumed that theories of strict
liability have materially altered a maker's or seller's liability for physical
harm resulting from a dangerous condition characteristic of the product
causing injury as well as all others of like kind. If there is to be any kind
of liability without fault, based on the capacity of an enterprise to bear
* Dean, The University of Texas School of Law. Member, American Law Institute. A.B.
1924, LL.B. 1931, University of Texas; S.J.D. 1936, Harvard.
1. E.g., James, The Untoward Effects of Cigarettes and Drugs; Some Reflections on Enter-
prise Liability, 54 CALIF. L. Rav. 1550 (1966); Keeton, Products Liability-Liability Without Fault
and the Requirement of a Defect, 41 TEXAS L. REV. 855 (1963); Noel, Products Defective Because
of Inadequate Directions Or Warnings, 23 Sw. L.J. 256 (1969); Prosser, The Fall of the Citadel
(Strict Liability to the Consumer), 50 MINN. L. REV. 791 (1966); Wade, Strict Tort Liability of
Manufacturers. 19 Sw. L.J. 5 (1965).
2. See Putman v. Erie City Mfg. Co., 338 F.2d 911 (5th Cir. 1964); Gottsdanker v. Cutter
Laboratories, 6 Cal. Rptr. 320 (Ct. App. 1960); Henningsen v. Bloomfield Motors, Inc., 32 N.J.
358, 161 A.2d 69 (1960); Goldberg v. Kolisman Instrument Corp., 12 N.Y.2d 432, 191 N.E.2d 81,
240 N.Y.S.2d 592 (1963).
3. See Caruth v. Mariani, II Ariz. App. 188, 463 P.2d 83 (1970); Elmore v. American
Motors Corp., 70 Cal. 2d 578, 451 P.2d 84, 75 Cal. Rptr. 652 (1969); Darryl v. Ford Motor Co.,
440 S.W.2d 630 (Tex. 1969); Noel, Products Liability: Bystanders, Contributory Fault and Unu-
sual Uses, in Proceedings of the Judicial Conference of the Sixth Judicial Circuit of the United
States, 50 F.R.D. 321 (1970).
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and shift losses, it clearly should apply to a manufacturing enterprise's
failure to achieve intended results. On the other hand, recognition of the
socially desirable principle that the risk of miscarriages in the manufac-
turing process should be allocated to the manufacturer on the assump-
tion that losses will be shifted to consumers by charging higher prices
for the products, does not logically require the abandonment of fault as
a basis for shifting losses resulting from hazards inherent in the product
as designed. Great practical difficulties are involved in the description
and allocation of these risks to the manufacturer, and there is wide
disagreement about the theoretical justification and economic conse-
quences of so doing. These analytical problems are particularly apparent
in the case of drugs and cosmetics because in the process of their manu-
facture, distribution, and use, the resulting benefits to the many4 have
come at a high cost to the few.5 In order to assess the possible applicabil-
ity of strict liability for harmful effects caused by products made in the
manner intended, three principal categories are suggested as a convenient
format for discussion: (1) products with side effects that are apparent
at the time of sale; (2) beneficial products whose harmful side effects are
preliminarily unknowable; and (3) products whose harmful side effects
outweigh their beneficial properties.
Drugs and other products that pose a known or knowable hazard
to some at the time of sale constitute the first category. Assuming rea-
sonable care is exercised in the marketing of the product, including the
giving of warnings and instructions, are there situations involving this
type of product when the manufacturer should be subject to liability
without proof of negligence? If not, and if negligence in the manner of
marketing the product is a prerequisite to recovery, should the same
defenses be available to the defendant as when a claimant seeks recovery
on the basis of a breach of the duty of ordinary care, or should only those
defenses that may be used by a manufacturer when the basis for recovery
is strict tort liability be permitted?
4. "Barely a generation ago, a doctor's little black bag contained only a small number of
effective drugs . . . . But after the discovery of the first sulfa drug in the Thirties, a doctor's
medical kit became a treasury of new drugs that helped to heal, cure and to save lives. With this
discovery, the world entered the age of chemotherapy-the treatment of disease with chemical
agents." National Observer, May 3, 1965, at 19, col. 1.
5. Whitmore, Allergies and Other Reactions Due to Drugs and Cosmetics, 19 Sw. L.J. 76
(1965).
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In the second category are drugs or other products that, after a
period of use, cause some users to have an adverse reaction which was
scientifically unknowable at the time of sale or even at the time of injury;
nevertheless, it appears that marketing can be conducted in such a way
as to justify its continued use. When the risk is discovered, potential
users normally would be given both notice of the risk and instructions
about how to avoid serious injury. Before the manufacturer discovers the
harmful side effects, however, some persons may be seriously injured by
the drug as a result of lack of notice. A drug called Aralen has been
productive of litigation in this category.'
The third category would include a drug or other product that, after
a protracted period of use, proves to be more harmful in its side effects
than the benefits to be gained from its use will justify. Within the scope
of this category are products that either the judiciary or legislature has
found to be defective and, therefore, unmarketable. The drug MER/29
and the vaccine Quadrigen are products that have produced litigation in
this area. 7 Many similarly dangerous products are withdrawn from the
market, either voluntarily or under coercion of some administrative
agency, before a final determination of their defective nature is made.
Prior to their withdrawal, however, some persons have been tragically
and permanently disabled. Some birth control pills, for example, re-
cently have been withdrawn from the market and claims involving their
debilitating effects are now being processed.8 When a drug proves to be
bad, negligence in its development and sale may be easily provable. In
other situations, however, this is not an easy task due to the enormous
discovery burdens of proving negligence. Yet, in any case arising in this
category, the issue must be faced of whether the manufacturer should
be held liable for injuries caused by a product before the existence of a
risk is established as a scientifically knowable fact.
6. Basko v. Sterling Drug. Inc., 416 F.2d 417 (2d Cir. 1969); Sterling Drug, Inc. v. Yarrow,
408 F.2d 978 (8th Cir. 1969); Cochran v. Brooke, 243 Ore. 89, 409 P.2d 904 (1966).
7. For a discussion of MER/29 see Rheingold, The MER/29 Story-An Instance of Suc-
cesslul Mass Disaster Litigation, 56 CALIF. L. REv. 116 (1968); Keeton, Some Observations About
the Strict Liability of the Maker of Prescription Drugs: The Aftermath of MER/29, 56 CALIF. L.
REV. 149 (1968). See also Roginsky v. Richardson-Merrell, Inc., 378 F.2d 832 (2d Cir. 1967); Blum
v. Richardson-Merrell, Inc., 268 F. Supp. 906 (D. Md. 1965); Bennett v. Richardson-Merrell, Inc.,
231 F. Supp. 150 (E.D. Ill. 1964); Toole v. Richardson-Merrell, Inc., 251 Cal. App. 2d 689, 60
Cal. Rptr. 398 (1967); McLeod v. W. S. Merrell Co., 174 So. 2d 736 (Fla. 1965); Lewis v. Baker,
243 Ore. 317, 413 P.2d 400 (1966); Cudmore v. Richardson-Merrell, Inc., 398 S.W.2d 640 (Tex.
Civ. App. 1965). For a discussion of Quadrigen see Parke, Davis & Co. v. Stromsodt, 411 F.2d
1390 (8th Cir. 1969); Tinnerholm v. Parke, Davis & Co., 411 F.2d 48 (2d Cir. 1969).
8. Two claims involving oral contraceptives are reported to have been settled, one in the
amount of S85,000 and another for $215,000. 14 PERSONAL INJURY NEWSLETTER 286, 287 (1971).
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II. LIABILITY FOR KNOWN OR KNOWABLE RISKS
It can be confidently said at the outset that no jurisdiction has
imposed liability on a manufacturer simply because his product caused
harm when it was used as intended. The mere fact that when marketing
the product the manufacturer knew, or should have known, that some
persons would suffer an idiosyncratic, allergic, or other adverse reaction
is an insufficient basis for recovery. In Davis v. Wyeth Laboratories,
Inc.,9 for example, it was contended on behalf of the plaintiff, who had
contracted polio after receiving a dose of Sabin oral polio vaccine, that
the manufacturer should be regarded as guaranteeing to each and every
user that the drug was fit and safe for his individual use, rather than
merely that it was reasonably fit and safe for public consumption. This
contention, had it been accepted, would have made a manufacturer liable
to anyone victimized in the course of proper and reasonable use of his
product. The court in Davis, however, held that it was unwilling to make
such a far-reaching change in the law. On the other hand, several dissent-
ing judges on the Fifth Circuit Court of Appeals, in a case involving lung
cancer caused by cigarette smoking, were willing to adopt that rule for
products with an unknown risk. t0 Their view was that once the jury
found both that the deceased used the product as intended and that death
resulted from lung cancer which developed as a consequence, no further
issue remained to be decided before damages could be assessed.
While it is clear that a manufacturer is not an insurer against harm
that may result from even known or knowable risks, it is often asserted
and assumed that recovery is sometimes obtainable on a strict liability
theory as well as the traditional negligence theory." If this is true, it must
be because it is thought that even a nonnegligent manufacturer should
be held liable under certain circumstances for harm resulting to a user,
either notwithstanding the user's awareness of the risk or because the
user, for some reason, was unaware of the risk.
9. 399 F.2d 121 (9th Cir. 1968).
10. Green v. American Tobacco Co., 409 F.2d 1166, 1168 (5th Cir. 1969) (Brown, Coleman,
and Godbold, J.J. dissenting). Judge Brown, in his dissenting opinion, said, "I reject the idea that
the enlightened Supreme Court of Florida will tolerate a commercial system that sells with impunity
ostensibly innocuous products, but which in fact have lethal consequences." Id. at 1170. In the
course of its tortuous litigation, this case produced 3 other appellate opinions reported as follows:
391 F.2d 97 (5th Cir. 1968); 325 F.2d 673 (5th Cir. 1963); 304 F.2d 70 (5th Cir. 1962).
11. See Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1969); Crotty v. Sharten-
berg's-New Haven, Inc., 147 Conn. 460, 162 A.2d 513 (1960); Bianchi v. Denholm & McKay Co.,
302 Mass. 469, 19 N.E.2d 697 (1939); RESTATEMENT (SECOND) OF TORTS § 402A, comment j at
354 (1965); Noel, Products Defective Because of Inadequate Directions or Warnings, 23 Sw L.J.
256, 267 (1969); Traynor, The Ways and Meanings of Defective Products and Strict Liability, 32*
TENN. L. REV. 363, 373 (1965).
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A. The Knowledgeable User
There is much support for the general proposition that the con-
sumer's ignorance constitutes the basis for imposing liability on the
manufacturer. The consumer has a right to know or be informed about
a product's dangerous characteristics against which he must be pro-
tected. Yet, unless the manufacturer fails, especially in the provision of
safety features, to conform to the normal and reasonable expectations
of those for whose use the product is intended,1 2 it cannot be held liable
on either a negligence or strict liability theory. Moreover, as a matter
of public policy, it can be reasonably argued that economic efficiency
in the satisfaction of consumer demands would be best promoted by
allocating losses for injuries resulting from the use of products to the
consumer, so long as he is adequately informed about the risks involved
and the incidence of harm from these risks.1 3 Under this rationale a
consumer would have no right, as against the manufacturer, to be secure
from harm caused by dangerous products except the right to be in-
formed." If this theory were adopted, safety legislation that requires the
elimination of an open and obvious danger and that interferes with
voluntary market arrangements would necessarily be suspect.
No one would deny that the user's knowledge of the risks involved
in the use of a product is relevant to the issue of the manufacturer's
liability. The question, however, is whether it should in all circumstances
be conclusive. The utility of a product can be outweighed by the magni-
tude of the danger related to its use even when utmost care is exercised
by all concerned. Thus, a drug or cosmetic might justifiably be regarded
as a bad product by a jury, or by those who have legislative powers in
12. Schemel v. General Motors Corp, 384 F.2d 802 (7th Cir. 1967) (car designed so it could
be driven at a speed of 11 5 miles per hour is not unreasonably dangerous since the danger is neither
latent nor concealed); Bollmeier v. Ford Motor Co., 265 N.E.2d 212 (I11. App. 1970) (although
the definitions of the term "defect" in the context of products liability law use varying language,
they all rest upon the common premise that those products are defective which are dangerous
because they fail to perform in the manner reasonably to be expected); Murphy v. Cory Pump &
Supply Co., 47 I11. App. 2d 382, 197 N.E.2d 849 (1964) (no guard in front of rotary lawnmower
blade, but court concluded that no one was misled by it). The RESTATEMENT (SECOND) OF TORTS
§ 402A, comment i at 352 (1965) provides in part that in order to find an article unreasonably
dangerous it "must be dangerous to an extent beyond that which would be contemplated by the
ordinary consumer who purchases it, with the ordinary knowledge common to the community as
to its characteristics."
13. See Calabresi, Transaction Costs, Resource Allocation and Liability Rules-A Com-
iment, 11 J. LAW & EcON. 67 (1968); Coase, The Problem of Social Cost, 3 J. LAW & EcON. I
(1960).
14. For further comments on this issue see Keeton, Product Liability-Inadequacy ofInfor-
mation, 48 TEXAS L. REV. 398, 399 (1970).
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the matter, even though its dangers are obvious or have been brought to
the consumer's attention.
Although there seems to be very little authority that would support
recovery by a consumer-user who was made aware, not only of the risk
itself, but also of the best means known for avoiding it; I would argue
that the law remains unsettled. The obvious nature of a particular danger
in a mechanical product, for example, does not necessarily preclude a
finding that it is either unfit for its intended purpose or unreasonably
dangerous, nor does it prevent a finding of negligence on the part of the
manufacturer. 15 Therefore, it is submitted that a user's awareness of the
risk involved should not preclude his recovery if, notwithstanding his
awareness of the risk, a fact-finder can reasonably conclude that the
product should not have been marketed. This does not mean that negli-
gence could not serve as the basis for recovery, but it does mean that
assumed risk should not necessarily be a defense and that a doctor's
knowledge of the risks involved in the use of a prescription drug ought
not to preclude recovery.'"
It is often assumed that a product is neither unfit nor unreasonably
dangerous if the normal person would not have any adverse reaction to
it.17 This assumption has been rejected by some courts in cosmetic cases
holding that an allergic victim can recover on proof that he is a member
of an appreciable class of persons who are sensitive to some ingredient
in the product,18 provided this fact was scientifically verifiable at the time
15. Wright v. Massey-Harris, Inc., 68 Il1. App. 2d 70, 215 N.E.2d 465 (1966) (self-propelled
corn-picker regarded as unreasonably dangerous even though it was clearly no more dangerous than
it appeared to be); Palmer v. Massey-Ferguson, Inc., 476 P.2d 713, 719 (Wash. Ct. App. 1970):
"[A] rule which excludes the manufacturer from liability if the defect in the design of his product
is patent but applies the duty if such a defect is latent is somewhat anomalous . . . . The law, we
think ought to discourage misdesign rather than encouraging it in its obvious form."
16. This is contrary to the position taken in the RESTATEMENT (SECOND) OF TORTS § 402A,
comment n at 356 (1965), which provides: "Contributory negligence of the plaintiff is not a defense
when such negligence consists merely in a failure to discover the defect in the product, or to guard
against the possibility of its existence. On the other hand the form of contributory negligence which
consists in voluntarily and unreasonably proceeding to encounter a known danger, and commonly
passes under the name of assumption of risk, is a defense under this section as in other cases of
strict liability."
17. Scientific Supply Co. v. Zelinger, 139 Colo. 568, 341 P.2d 897 (1959); Jacquot v. Win.
Filene's Sons Co., 337 Mass. 312, 149 N.E.2d 635 (1958); Zampino v. Colgate-Palmolive Co., 10
Misc. 2d 686, 173 N.Y.S.2d 117 (Sup. Ct. 1958), rev'd, 8 App. Div. 2d 304, 187 N.Y.S.2d 25
(1959); Barrett v. Kresge Co., 144 Pa. Super. 516, 19 A.2d 502 (1941). InJacquot the court said,
"For a plaintiff to recover for breach of an implied warranty of fitness of a garment, a cosmetic,
or comparable product [there must be proof] that the article was unfit to be worn or used by a
normal person." 337 Mass. at 315, 149 N.E. 2d at 638.
18. Gober v. Revlon, Inc., 317 F.2d 47 (4th Cir. 1963) (nail polish); Reynolds v. Sun Ray
Drug Co., 135 N.J.L. 475, 52 A.2d 666 (Ct. Err. & App. 1947) (lipstick); Esborg v. Bailey Drug
Co., 61 Wash. 2d 347, 378 P.2d 298 (1963) (hair tint). See generally Noel, supra note 11, at 295;
Dickerson, Products Liability: How Good Does a Product Have To Be?, 42 IND. L.J. 301, 330
(1967).
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of sale. Both the assumption that only a user who suffers a normal
reaction can recover and the requirement that an allergic user be a
member of an appreciable class are unsound. The typical consumer
never expects to be in the sensitive group and, therefore, can be expected
to take a chance. " Moreover, if other products would serve the same
purpose and cause fewer or less serious adverse reactions, the mere fact
that neither the "normal" person nor an appreciable class of users
would suffer an adverse reaction should not prevent either a finding
impugning the product or a finding of negligence against the maker. This
is especially true when the adverse reaction is disastrous 20 since a reason-
able person could well conclude that the harm caused by the product
outweighed its utility. Furthermore, if there is any appreciable risk of
serious harm to some persons, whether or not the reactions are desig-
nated as allergic or idiosyncratic, it would be feasible to allocate these
losses to the manufacturer.
B. The Uninformed User
One who is injured by either a prescription drug or an over-the-
counter drug or cosmetic may, for one of two reasons, have been una-
ware at the time of use of the risk involved or the means of avoiding
harm. The maker may have made no attempt to communicate his
knowledge of the risk, or, notwithstanding his efforts to inform, the user
may have never actually become aware of it. Thus, claimants have often
asserted the following as separate grounds of recovery: (1) A product
made according to the intended design was, nevertheless, "unfit" or
"unreasonably dangerous"; and (2) even if the product itself was not
defective, adequate information was never received by the consumer
about its inherent risks. In the vast majority of these cases, however, the
recovery, if any, was obtained on a theory of negligence in failing either
to give any warning or to take adequate measures to convey the neces-
sary information.
2'
Assuming that a risk, known or knowable on the part of the maker,
is one that no reasonable person would want to be subjected to without
19. Keeton, supra note 6.
20. But see Cochran v. Brooke, 243 Ore. 89, 409 P.2d 904 (1966).
21. Parke, Davis & Co. v. Stromsodt, 411F.2d 1390 (8th Cir. 1969); Tinnerholm v. Parke,
Davis & Co., 411 F.2d 48 (2d Cir. 1969); Sterling Drug, Inc. v. Yarrow, 408 F.2d 978 (8th Cir.
1969); Rumsey v. Freeway Manor Minimax, 423 S.W.2d 387 (Tex. Civ. App. 1968). For a discus-
sion of the subject see Dillard & Hart, Product Liability: Directions for Use and the Duty to Warn,
41 VA. L. REV. 145 (1955); Noel, Manufacturer's Negligence of Design or Directions for Use of a
Product, 71 YALE L.J. 816 (1962); Noel, supra note 11.
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sufficient information to avoid it if he chooses, should the maker be held
strictly liable for causing a victim to be subjected to this risk or should
his liability be based on whether he implements reasonable safeguards?
Imposition of strict liability on the maker, without regard to the precau-
tions of intermediate sellers, doctors, or the victim himself, would be a
far cry from holding a manufacturer responsible for miscarriages in the
manufacturing process. Perhaps no liability should be imposed on a
manufacturer for miscarriages in the communication process unless he
is negligent. If this position is taken, one could argue that the negligence
rules of proximate cause and contributory negligence also would be
applicable to a products liability case. On the other hand, the basic issue
in a products liability case ought to be whether the manufacturer con-
structed, designed, or marketed the product in a manner that results in
an unreasonable risk of harm to those who might be injured in the course
of its use. Under this view, contributory negligence should either be a
defense in all of these situations or in none of them, the position appar-
ently taken in the Restatement (Second) of Torts.2 2 Dean Prosser has
said that when a products liability case involves the question of reasona-
ble warning, the liability is not distinguishable from that which would
be found in an ordinary negligence case.Y It is distinguishable from
negligence liability, however, if the defense of contributory negligence is
not regarded as a bar to recovery.
In Davis v. Wyeth Laboratories, Inc.,
24 the court, with one judge
dissenting, applied a kind of strict liability. The plaintiff had ingested
Type III Sabin oral polio vaccine at a mass immunization project. At
the time he was 39 years of age. No effort was made by either the
manufacturer or those managing the project to provide any warning
about the risk of contracting polio from the vaccine. Since the need for
polio immunization diminishes with advancing age and because there is
a small potential risk, especially to adults, of contracting polio from
Sabin oral vaccine, the desirability of using this vaccine to immunize a
person 39 years old is questionable. According to the court, the situation
necessitated a "true choice judgment, medical or personal," because the
"risk of contracting the disease without immunization was about as
22. RESTATEMENT (SECOND) OF TORTS § 402A, commentj at 353 (1965).
23. "In occasional cases, such as the principal one [Davis v. Wyeth Laboratories, Inc.,] 399
F.2d 121 (9th Cir. 1968) the liability has been put on the basis of implied warranty, or strict liability
in tort, on the ground that a product sold without warning is unsafe or 'defective'. But since the
question is one of reasonable warning, the liability is not distinguishable from negligence." W.
PROSSER & J. WADE, CASES AND MATERIALS ON TORTS 727 n.2 (5th ed. 1971).
24. 399 F.2d 121 (9th Cir. 1968).
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great (or small) as [plaintiffs] risk of contracting it from the vaccine." '
Therefore, even in the absence of a finding of negligence, the court held
that the manufacturer was liable to the plaintiff because he received no
warning of the material risks involved in taking the vaccine or of the
dubious value of the protection thereby provided.
There is not very much difference between requiring disclosure, or
an attempt at disclosure, of a risk that would be regarded as material
both by a reasonable man in giving or withholding consent to a medical
procedure and by a doctor in deciding whether to prescribe a drug for a
particular patient, and requiring the same warning only when a reasona-
ble man would give it. The Wyeth case, however, illustrates a situation
in which one could justifiably conclude, as the trial judge apparently did,
that the difficulty of trying to communicate the relative dangers involved
to all users precluded a finding of negligence, and yet agree with the
court of appeals that a true, choice judgment was involved. It is not at
all clear what the court would have done if some measures had been
taken to provide notice, such as putting up posters, and the issue before
the court had been the sufficiency of these precautions. If the negligence
standard for when an effort should be made to communicate a risk is
abandoned in this type of case, how can one set up a realistic standard
for deciding what the measures to be taken should be? While it can be
argued that the plaintiff should recover unless it is found that he either
knew or should have known about the risk from the notices that were
given, there would appear to be no support for this position.
Another drug case, Basko v. Sterling Drug, Inc.,"8 differs from
Wyeth in that after the danger of possible blindness resulting from the
use of its drugs became known, various measures were taken by the
manufacturer to warn doctors who might prescribe them. Despite these
efforts, however, the plaintiff suffered permanent eye injury. In rejecting
the plaintiff's contention that she was entitled to a directed verdict as a
matter of law, the court said that with respect to the question of liability
for failure to warn, negligence and strict liability concepts are virtually
identical. Therefore, it upheld a charge requiring the jury to find as a
prerequisite to recovery that reasonable efforts to warn were not made.
The court distinguished Wyeth by saying that there, the evidence was
overwhelming that the manufacturer not only knew that the vaccine was
being dispensed without any warning of its deleterious effects, but also
attempted to assure all members of the community that they should take
it.
25. Id. at 130.
26. 416 F.2d 417 (2d Cir. 1969).
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III. THE UNKNOWABLE RISK
One important, fundamental question that has not been finally re-
solved is whether the manufacturer of a drug or other product intended
for intimate bodily use should be liable for a harmful reaction that
occurs before the harmful propensities of the product become known.
Arguably, the manufacturer's failure to discover the risk could occur in
one of three different situations: (1) his lack of knowledge was due to
negligence; (2) although the hazard was either scientifically known or
knowable, the manufacturer in the exercise of ordinary care failed to
discover it; or (3) the risk would not have been a scientifically discovera-
ble fact. Thus, it would seem that in discussing the liability of the manu-
facturer for unknowable risks, the distinction should be between risks
that the manufacturer ought to have discovered in the exercise of ordi-
nary care and risks of which he was justifiably unaware at the time of
sale. The issue, then, is simply whether a finding of negligence should
be a prerequisite to recovery against a manufacturer for a harmful reac-
tion attributable to an unknown hazard.
The initial holdings on this issue involved the claims of lung cancer
victims against cigarette manufacturers. Of the three courts passing on
the question, one concluded that the manufacturer could be held liable
if the unknowable risk made the product unfit or defective. 7 The two
other courts, however, held that in order to recover, the plaintiff must
prove that the warranted product contained an element from which, on
the basis of existing human knowledge at the time of sale, harm might
be expected to flow.2 8 Two arguments have been advanced in support of
the latter position. First, an unknowable risk ought to be borne by the
individual in common with his fellow humans and insured against in the
same fashion as death or disease, 29 because, unlike ordinary miscarriages
or failures, it is not an inevitable by-product of the manufacturing pro-
27. Green v. American Tobacco Co., 154 So. 2d 169 (Fla. 1963). In its opinion the court
said: "No reasonable distinction can, in our opinion, be made between the physical or practical
impossibility of obtaining knowledge of a dangerous condition, and scientific inability resulting
from a current lack of human knowledge and skill.
"The contention that the wholesomeness of a product should be determined on any standard
other than its actual safety for human consumption, when supplied for that purpose, is a novel
proposition in our law, and one which we are persuaded has no foundation in decided cases." Id.
at 171, 173.
28. Ross v. Phillip Morris & Co., 328 F.2d 3 (8th Cir. 1964); Lartigue v. R.J. Reynolds
Tobacco Co., 317 F.2d 19 (5th Cir.), cert. denied, 375 U.S. 865 (1963) (applying Louisiana law).
29. Connolly, The Liability of a Manufacturer for Unknowable Hazards Inherent in his
Product, 32 INs. COUNSEL J. 303 (1965).
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cess. Secondly, a risk cannot be spread unless it is known. Since, as
Fleming James has observed, the inevitability of allergic, idiosyncratic,
and other adverse reactions from elements in drugs and cosmetics is as
well known as is the inevitability and certainty of failures in construc-
tion 30 it is difficult to justify a distinction between an unreasonably
dangerous condition arising from a miscarriage in the manufacturing
process and an unreasonably dangerous condition attributable to so-
ciety's lack of scientific development. Nevertheless, even though the
existence and magnitude of scientifically unknowable risks are as mea-
surable as the likelihood of construction defects, it can reasonably be
argued that the activity of manufacturing drugs should not be required
to bear accident losses resulting therefrom. Moreover, a number of con-
siderations can be cited in support of this position. It is not the limita-
tions of the enterprise, but the limitations of mankind's technology that
account for the manufacturer's ignorance. In addition, the effect that
this liability would have on the price of drugs and the development of
new products is unclear. Furthermore, if any new' products would, in
fact, be kept off the market, it might be those most worth the risk.
31
My position has been and remains that, whatever the reason may
be, if the sale of a product exposes the user or others to an unreasonable
risk of harm, liability for harm resulting from that risk should follow.
Under this rationale, the manufacturer of a product would be liable for
all harm resulting from an unknowable risk, (I) if the product proved
ultimately to be bad, or (2) if the user of the product was subjected to
an unreasonable risk in that he was deprived of the means for avoiding
harm from it. Although there is not much judicial authority for either
of these assertions, they are desirable from a practical standpoint in light
of the plaintiffs difficult burden of proof in a negligence action. The
time and expense required to investigate all the procedures of those who
make and sell a new drug is enormous, and may prevent an individual
litigant from gathering the necessary facts to prove negligence when it
does, in fact, occur. Moreover, the economic costs of such an investiga-
tion and the administrative difficulties that are involved in the fact-
finding and decision-making processes argue eloquently for nonfault and
enterprise liability when feasible. The litigation concerning MER/29, an
30. In James, The Untoward Effects of Cigarettes and Drugs: Some Reflections on Enter-
prise Liability, 54 CALIF. L. REV. 1550, 1557 (1966), the author says: "That the specific is unknown
and unknowable in advance is not as significant as he (Connolly) seems to think, where the risk is
of a type which is foreseeable" (emphasis in original).
31. Connolly, supra note 29, at 306.
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anticholesterol drug that caused cataracts and other serious damage to
the eyes of some users, amply illustrates these difficulties .
3 2
While very few courts have discussed the problem of liability for
harm resulting from good products before the manufacturer knew or
should have known of the risk, some of the language in the Basko and
Wyeth cases is instructive. In Basko claims were filed against a manu-
facturer of a drug called Aralen, which is a trade name for chloroquine
phosphate. This drug was developed and sold for the treatment of arthri-
tis. It ultimately became known that continued application over a pro-
tracted period of time would cause blindness in some users. On the other
hand, the onset of any adverse reaction could be detected in time to avoid
irreversible damage. In purporting to apply Connecticut law, the Court
of Appeals for the Second Circuit said: "Defendant did not warn of the
risk of idiosyncratic reaction until 1960. Thus, the only real question
with respect to Aralen is whether the risk was either knowable or reason-
ably foreseeable at a time when the plaintiff was still taking the drug.1
33
The opinion in Wyeth contains similar language regarding the manufac-
turer's duty: "[W]hen Type I II Sabin vaccine was first licensed by the
government in early 1962 and first manufactured and sold by Wyeth,
there was no known or foreseeable risk involved in taking it. Thus,
Wyeth could not initially be expected to warn of unknown dangers.
34
Therefore, both Basko and Wyeth support the proposition that a manu-
facturer is not liable for harm resulting from a good product until after
the manufacturer knew or should have known of the risk of harm and
failed to give adequate warning. There apparently is no judicial authority
or language to the contrary, but this could be partially explained by the
fact very few courts have discussed the question.
If a product is found to be bad after a period of use, there is more
uncertainty with respect to the manufacturer's liability to those who
were injured prior to knowledge of the risk. Such products are usually
withdrawn from the market, as in the case of MER/29 and Quadrigen.
Claims resulting from the marketing of MER/29 produced two deci-
sions, one in Oregon35 and one in Texas, 36 denying liability. The Oregon
Supreme Court adopted the proposition that no warranty is applicable
32. Keeton, supra note 6; Rheingold, The MER Story-An Instance of Successful Mass
Disaster Litigation, 56 CALIF. L. REv. 116 (1968).
33. Basko v. Sterling Drug, Inc., 416 F.2d 417,426 (2d Cir. 1969).
34. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121, 129 (9th Cir. 1968).
35. Lewis v. Baker, 243 Ore. 317,413 P.2d 400 (1966).
36. Cudmore v. Richardson-Merrell, Inc., 398 S.W.2d 640 (Tex. Civ. App. 1965), cert.
denied, 385 U.S. 1003 (1967).
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to the sale of an unadulterated, uncontaminated prescription drug ap-
proved by the Federal Drug Administration. In Texas the intermediate
appellate court adopted Judge Wisdom's view in one of the cigarette
cases 37 stating that since medical knowledge was not developed suffi-
ciently to enable the defendant to reasonably have discovered that
MER/29 caused cataracts, there should be no liability. There is, of
course, a fundamental difference between MER/29 and cigarettes, be-
cause cigarettes have never been withdrawn from the market nor re-
garded as bad per se, whereas MER/29 had been banned when the
plaintiff's claim was brought.
In contrast to the Aralen cases, the two decisions involving Quadri-
gen claims, one in the Second Circuit38 and one in the Eighth Circuit,39
contain language that could be regarded as indicating that the manufac-
turer would be liable for an injury that occurred before the risk of harm
from Quadrigen was knowable. In both cases the victimized infant was
innoculated within four months of the initial commercial distribution in
July 1959 and well before the vaccine was withdrawn from the market
in 1961 as unsafe. The children contracted an encephalopathy, which left
them severely mentally retarded. In each case there were trial court
findings of negligence and breach of warranty, and in each the defen-
dant's principal defensive theory was the insufficiency of the evidence to
justify a finding of causal connection between the vaccine and the subse-
quent contraction of encephalopathy. The Second Circut said that it was
unnecessary to discuss liability resting on negligence theories since "it
cannot be disputed (and appellant does not disagree) that a drug manu-
facturer impliedly warrants under New York law that its products will
not prove to be unreasonably dangerous .... "0 The Eighth Circuit
concluded that the evidence was sufficient to justify findings of negli-
gence as well as breach of warranty.4 1 While the issue of liability for an
unknowable risk could hardly be said to have been considered by either
court, it does appear that both courts were willing to consider on the
issue of warranty liability a great deal of evidence related to the danger-
ousness of Quadrigen that was not available until after the vaccine had
been sold and administered.
37. Lartigue v. R.J. Reynolds Tobacco Co., 317 F.2d 19, 24 (5th Cir. 1963).
38. Tinnerhold v. Parke, Davis & Co., 411 F.2d 48 (2d Cir. 1969).
39. Parke, Davis & Co. v. Stromsodt, 411 F.2d 1390 (8th Cir. 1969).
40. 411 F.2d at 53.
41. 411 F.2d at 1399.
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IV. CONCLUSION
It is suggested that a court should find a drug or cosmetic to be
unreasonably dangerous at the time of sale, thereby subjecting the manu-
facturer to strict liability, if at the time of trial the product is found to
be bad in the sense that the possibility of adverse reactions from its
proper use outweighs the potential benefits to consumers. A product can
be found to be bad either because the political authorities, through
legislative or administrative procedures, have reached that conclusion or
because a reasonable man would do so. Another suggested basis for
regarding a drug or cosmetic as unreasonably dangerous at the time of
sale would be a finding at the time of trial that the product's sale without
the manufacturer's supplying or attempting to supply additional infor-
mation about potential hazards would subject those who use, or upon
whom the product is used, to an unreasonable risk of harm. If at the
time of trial these additional precautionary measures are required by the
political authorities or if a reasonable man would conclude that these
measures should be taken, a manufacturer who has failed to take them
would be held liable for resulting harm to users because he has subjected
themto an unreasonable risk.
Perhaps the manufacturer's liability should be further extended in
some manner to those who suffer serious and tragic reactions from good
drugs properly used and marketed, even when the risk was known to the
victim. More often than not, however, the situation would be one in
which the drug was used as a last resort to save life or prevent bodily
injury, and, therefore, the damages would be speculative. In any event,
this liability has not yet been imposed, and it is extremely doubtful that
it should be.
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